35 results about "Cell permeable peptide" patented technology

The present invention relates to the delivery of biologically active molecules, such as peptides, into the interior of cells by administering to the cells a complex comprising the molecule linked to an importation competent signal peptide. Such delivery can be utilized, for example, to treat and / or prevent inflammatory conditions, e.g., but not limited to, systemic inflammatory reactions such as endotoxic shock, localized inflammatory reactions such as inflammatory skin diseases and conditions, and inflammatory diseases such as autoimmune diseases.

The invention belongs to the field of biomedicine and relates to a human original cell permeable peptide hPP3 and usage thereof. The cell permeable peptide hPP3 provided by the invention has a cell membrane permeation function, thereby being capable of carrying such large molecules as protein to enter a plurality kind of cells in a transmembrane manner; since the peptide segment is derived from human protein, the possibility of causing human body immune response is small, the potential insecurity factors are relatively small, so that the hPP3 can serve as a transmembrane transport carrier having brilliant development prospect of such bioactive molecules as protein, polypeptide, and the hPP3 can be used as an intracellular drug transport carrier.

The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2 / DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer.

A sustained-release microsphere formulation containing a short chain deoxyribonucleic acid or a short chain ribonucleic acid as an active ingredient, which has improved sustained-release properties and long-lasting efficacy, is provided. A fine particle formulation, encapsulating stably a short chain deoxyribonucleic acid or a short chain ribonucleic acid, being capable of inhibiting, for a long period, expression of a specific protein related to a disease, and which can be administered by injection or transmucosally, and a production method of the same are provided. A sustained-release microsphere formulation containing a short chain deoxyribonucleic acid or a short chain ribonucleic acid, particularly siRNA, as an active ingredient, especially a sustained-release microsphere prepared through a w1 / o / w2 type emulsion, is characterized in that a positively charged basic substance, such as arginine, polyethylenimine, a cell permeable peptide, poly-L-lysine or poly-L-ornithine, is included in an in vivo degradable polymer.

The invention discloses a novel cell-permeable peptide capable of efficiently mediate the delivery of drugs into cells, and further provides applications of the novel cell-permeable peptide in treatment of tumors.

The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof.According to the present invention, cationic cell permeable peptides derived from human bone morphogenetic protein-4 have no toxicity and immuno-genicity and thus exhibit high stability as compared to viral peptide delivery vehicles, and can transport cell impermeable material into cells and into an organism without any damage to cell or material, thereby significantly increasing target gene expression. In addition, the peptide may be applied to clinical use without having to undergo a large number of processes and mass-produced, such that the present invention may be useful in the development of a drug delivery system and treatment technologies using said peptide.

The invention provides cell permeable peptides and peptide agents that inhibit anti-apoptotic processes in cancer cells to promote tumor cell death, as well as a method for providing therapeutic treatment for cancer. The composition may be delivered in conjunction with a conventional chemotherapeutic agent to provide a synergistic effect that significantly increases the effectiveness of the chemotherapeutic agent to destroy cancer cells. The invention also provides kits or systems for cancer therapy, comprising at least one peptide agent for inhibiting the anti-apoptotic effects of NF-kB and at least one chemotherapeutic agent for stimulating the cellular apoptotic pathway.

The invention provides for a cell permeable peptide conjugated to an insulin compound for improved cell penetration of the insulin moiety. The composition may be delivered by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means for the treatment, including prophylaxis of Type I, Type II diabetes, prediabetes and / or metabolic syndrome.

The invention relates to a high-transdermal-absorption subcutaneouse targeted release factor, a construction method and application. According to the codon preference of an expression host, gene segments of three parts including hEGF, cell permeable peptides and a subcutaneouse endogenous protease cleavage site are optimized, spliced together and connected in expression plasmid to construct an expression carrier of high-transdermal-absorption subcutaneouse targeted release hEGF, and the expression carrier is converted in hosts such as escherichia coli so that efficient expression production can be achieved. By means of the method, the defect that the percutaneous permeability of hEGF used as a biomacromolecule substance is low is overcome, the hEGF can efficiently span a skin cuticula and can be released under skin in a targeted manner to promote fibroblast proliferation and other effects, and therefore the actual effects on the aspects of skin protection, acne removing, wrinkle removing, skin whitening and the like are remarkably improved, and a new perspective and a new method are provided for development and production of related beauty products and biological medicine.

The number of peptides having an ability to bind to a cell or penetrate into a cell is narrowed down by being selectively enriched from a random peptide library with a diversity of not less than one hundred millions of peptides using a phage surface display technique, and then cytoplasmic transfer is evaluated by using protein synthesis inhibition as an indicator by adding to a cell, a fusion body of the selectively enriched peptide and a protein synthesis inhibitory factor (PSIF) that cannot solely penetrate into the cell.

The invention relates to compositions and methods for facilitating fusion of a virus with a cell and for facilitating virus-mediated transduction of a nucleic acid into a cell. The invention further relates to the use of cell permeable peptides to facilitate fusion of a virus with a cell.

The invention provides cell permeable peptides and peptide agents that inhibit anti-apoptotic processes in cancer cells to promote tumor cell death, as well as a method for providing therapeutic treatment for cancer. The composition may be delivered in conjunction with a conventional chemotherapeutic agent to provide a synergistic effect that significantly increases the effectiveness of the chemotherapeutic agent to destroy cancer cells. The invention also provides kits or systems for cancer therapy, comprising at least one peptide agent for inhibiting the anti-apoptotic effects of NF-kB and at least one chemotherapeutic agent for stimulating the cellular apoptotic pathway.

A fluorochrome probe is disclosed. The structure of the fluorochrome probe is shown as a formula (I) that is MGVADLIKKFESISKEE-GGGGK-R1-GG-rRrRrRRR, wherein the MGVADLIKKFESISKEE is an amino acid sequence of an actin recognition group, the GGGGK is a first connecting group, the R1 is a fluorochrome group, the GG is a second connecting group, the rRrRrRRR is an amino acid sequence of a cell permeable peptide, the r is D-arginine, and the R is L-arginine. The fluorochrome probe can specifically label living-cell endogenic actin, and obtain super-resolution microimaging with a higher resolution after fluorescence imaging of the living-cell endogenic actin is achieved.

A method of preparing a reprogramming induced pluripotent stem cell from a human-derived somatic cell using a fusion protein in which a reprogramming inducing factor and cell permeable peptide (CPP) are fused, and a fusion protein in which a reprogramming inducing factor and a cell permeable peptide are fused are disclosed.According to the present invention, the induced pluripotent stem cell having high efficiency and high stability can be prepared by maximizing the effect of the reprogramming inducing transcription factor beyond the existing viral peptide transporter, in inducing the reprogramming of the somatic cell.

The invention discloses a non-viral gene vector for gene transfer. The non-viral gene vector for gene transfer is formed by connecting polyethyleneimine, heparin sodium and cell permeable peptides. The invention also provides a preparation method and use of the vector. The non-viral gene vector HPR is low in toxicity, high in transfection efficiency and good in clinical application prospect.

The present invention relates to the field of pharmaceutical preparations, and particularly to an oral calcitonin liposome and a lyophilized preparation thereof. The oral calcitonin liposome is characterized in that a water-soluble polypeptide drug calcitonin is encapsulated into an inner aqueous phase of a liposome or is tightly adsorbed on the surface of liposome membrane; then cell-permeable peptide Arg8 and a high molecular TMC are sequentially adopted to modify the surface of the liposome to prepare an oral calcitonin liposome with a characteristic of mucous membrane adhesion; and then a freeze drying treatment is performed to prepare a lyophilized preparation, wherein an average particle size of the preparation is less than 180 nm, and rat in vivo experiment results show that efficacy of the preparation is increased by 103 times compared with the efficacy of oral calcitonin solutions.

The invention belongs to the technical field of the medicine, relates to quercetin eye drops and a preparation method thereof, and specifically relates to quercetin hydroxypropyl-beta-cyclodextrin inclusion compound eye drops. The quercetin eye drops is prepared from the following components in weight volume percent: 0.1%-0.8% of quercetin, 0.025%-0.3% of penetration enhancer, 7%-30% of hydroxypropyl-beta-cyclodextrin, 0.005%-0.02% of bacteriostatic agent, 0.6%-1.5% of isoosmotic adjusting agent, 0.001%-0.05% of pH regulator, and the balance of water for injection. The penetration enhancer isone of the thiolated chitosan, chitosan or cell-permeable peptide (R8). The penetration enhancer is combined with the inclusion compound of the hydroxypropyl-beta-cyclodextrin of the quercetin to prepare the eye drops with good effect of preventing and treating cataract; the eye drops has the advantages of being good in cornea permeability, high in bioavailability, good in biocompatibility, and small in eye irritation, and has extensive development prospect.

The present invention discloses a novel oral composite nano-carrier formed from a lipid cell-permeable peptide and solid lipid nanoparticles, a preparation method and a use thereof. According to the present invention, a film dispersion-ultrasound method is adopted to prepare solid lipid nanoparticles for drug loading; then a lipid cell-permeable peptide and the drug-loaded solid lipid nanoparticles are incubated to construct a novel oral composite nano-carrier. According to the composite nano-carrier of the present invention, a special absorption way of the solid lipid nanoparticles in gastrointestinal tract and an absorption promotion effect of the cell-permeable peptide are utilized so as to effectively solve the absorption problem of difficultly-absorbed oral drugs, and improve oral bioavailability of drugs.

The invention discloses a novel chimeric antibacterial cell-permeable peptide T11N2. The amino acid sequence is as shown in SEQ ID NO:1. The novel chimeric antibacterial cell-permeable peptide T11N2 is a chimeric polypeptide formed by connecting a cell-permeable peptide Tat which has 11 amino acids on the basis of a high-activity antibacterial peptide N2. The antibacterial peptide T11N2 has a simple structure, low toxicity, safety, low cost and relatively easy synthesis, and is a novel chimeric antibacterial cell-permeable peptide capable of efficiently penetrating membranes and killing intracellular salmonella. The antibacterial peptide T11N2 disclosed by the invention can be applied to the fields of antibacterial drugs, food additives, cosmetics, feed additives and the like, and has a wide application value and market prospect.

The invention discloses application of superhigh pressure orange juice rich in endogenous cell permeable peptides in food, the superhigh pressure orange juice rich in endogenous cell permeable peptides is prepared by a superhigh pressure non-thermal processing method, the superhigh pressure of the superhigh pressure non-thermal processing method is 350-450 MPa, and the superhigh pressure time is 10-15 min. Orange juice is low-protein-content food, peptide substances are generally obtained from high-protein-content food, the separation and purification method of the orange juice is complex, natural extraction resources are limited, and the cost is high. According to the invention, the ultrahigh pressure orange juice rich in endogenous cell permeable peptides is obtained from the food orange juice with low protein content for the first time, and is not from addition. The non-covalent binding naturally exists among food components, and CPPs in the ultrahigh pressure orange juice rich in endogenous cell permeable peptides is in non-covalent binding with other active substances, so that the absorption of the food components is promoted.

Peptide system comprising at least one peptide blocking the presynaptic release of glutamate, said peptide having sequence SEQ ID NO 5: GRKKRRQRRRPPIEQSIEQEEGLNRS; and / or sequence SEQ ID NO 8: GRKKRRQRRRPPMSEYNATQSDYRER for use in treating pathologies associated with glutamate excitotoxicity.